ARTICLE | Clinical News
CTTQ's tyrosine kinase inhibitor gets Chinese approval for NSCLC
May 18, 2018 2:29 AM UTC
The State Drug Administration (formerly CFDA) approved Focus V anlotinib from Chia Tai Tianqing Pharmaceutical Group Co. Ltd. (Nanjing, China) to treat advanced non-small cell lung cancer.
CTTQ has Chinese rights to anlotinib from Advenchen Laboratories LLC (Moorpark, Calif.), which developed the multi-target receptor tyrosine kinase inhibitor and retains rights elsewhere...